Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Farnesoid X receptor (FXR): Structures and ligands. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/j.tibs.2006.08.002
10.1016/j.tibs.2006.08.002 · External reference
Analysis of nuclear receptor pseudogenes in vertebrates: how the silent tell their stories
10.1093/molbev/msm251 · 2008 · External reference
Hepatic farnesoid X-receptor isoforms α2 and α4 differentially modulate bile salt and lipoprotein metabolism in mice
10.1371/journal.pone.0115028 · 2014 · External reference
10.1074/jbc.m209505200
10.1074/jbc.m209505200 · External reference
Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications
10.1016/j.bbadis.2010.11.011 · 2011 · External reference
10.1016/j.cell.2019.01.036
10.1016/j.cell.2019.01.036 · External reference
10.1074/jbc.275.15.10918
10.1074/jbc.275.15.10918 · External reference
10.1016/s1097-2765(00)00051-4
10.1016/s1097-2765(00)00051-4 · External reference
Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk
2018 · External reference
10.1016/j.cmet.2005.09.001
10.1016/j.cmet.2005.09.001 · External reference
10.1084/jem.20171965
10.1084/jem.20171965 · External reference
Low retinol levels differentially modulate bile salt-induced expression of human and mouse hepatic bile salt transporters
10.1002/hep.22661 · 2009 · External reference
Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid
10.1016/j.jhep.2016.01.016 · 2016 · External reference
10.1074/jbc.m011610200
10.1074/jbc.m011610200 · External reference
Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system
10.1016/j.tiv.2016.11.014 · 2017 · External reference
10.1002/hep.30661
10.1002/hep.30661 · External reference
FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection
10.1152/ajpgi.00356.2017 · 2019 · External reference
Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis
10.1038/ncomms10713 · 2016 · External reference
Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases
10.1186/s12929-018-0475-8 · 2018 · External reference
Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver
10.1186/s13046-018-0781-8 · 2018 · External reference
Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2/STAT3 signalling via transactivation of SOCS3 gene
10.1111/jcmm.16083 · 2020 · External reference
The FXR agonist, obeticholic acid, suppresses HCC proliferation & metastasis: role of IL-6/STAT3 signalling pathway
10.1038/s41598-017-12629-4 · 2017 · External reference
10.1016/j.bbadis.2017.08.016
10.1016/j.bbadis.2017.08.016 · External reference
Obeticholic acid: first global approval
10.1007/s40265-016-0616-x · 2016 · External reference
10.1002/pro.3496
10.1002/pro.3496 · External reference
10.1016/j.aquatox.2010.02.020
10.1016/j.aquatox.2010.02.020 · External reference
Structure of the heterodimeric ecdysone receptor DNA-binding complex
10.1093/emboj/cdg569 · 2003 · External reference
Ligand binding and heterodimerization with retinoid X receptor α (RXRα) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding
10.1074/jbc.ra118.004652 · 2018 · External reference
10.1074/jbc.275.14.10638
10.1074/jbc.275.14.10638 · External reference
10.1172/jci0214505
10.1172/jci0214505 · External reference
Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes
10.1371/journal.pone.0105930 · 2014 · External reference
10.1002/hep.23450
10.1002/hep.23450 · External reference
10.1016/s1097-2765(03)00104-7
10.1016/s1097-2765(03)00104-7 · External reference
10.1074/jbc.ra118.004188
10.1074/jbc.ra118.004188 · External reference
10.1016/s1097-2765(03)00112-6
10.1016/s1097-2765(03)00112-6 · External reference
Discovery of natural products as novel and potent FXR antagonists by virtual screening
10.3389/fchem.2018.00140 · 2018 · External reference
Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor
10.1016/j.bbrc.2020.10.039 · 2021 · External reference
10.1038/s41467-019-10853-2
10.1038/s41467-019-10853-2 · External reference
10.1038/378681a0
10.1038/378681a0 · External reference
10.1016/j.tibs.2014.10.011
10.1016/j.tibs.2014.10.011 · External reference
Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone
10.1016/j.bbapap.2014.06.007 · 2014 · External reference
D3R Grand Challenge 2: blind prediction of protein-ligand poses, affinity rankings, and relative binding free energies
2018 · External reference
10.1002/cbic.201700059
10.1002/cbic.201700059 · External reference
The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism
2013 · External reference
10.1074/jbc.m114.630475
10.1074/jbc.m114.630475 · External reference
10.1080/13543784.2020.1763302
10.1080/13543784.2020.1763302 · External reference
10.1016/s1097-2765(00)80348-2
10.1016/s1097-2765(00)80348-2 · External reference
Potential of intestine-selective FXR modulation for treatment of metabolic disease
10.1007/164_2019_233 · 2019 · External reference
10.1002/cphy.c120023
10.1002/cphy.c120023 · External reference
10.1053/j.gastro.2013.05.042
10.1053/j.gastro.2013.05.042 · External reference
10.1016/s0140-6736(19)33041-7
10.1016/s0140-6736(19)33041-7 · External reference
10.1016/s0140-6736(14)61933-4
10.1016/s0140-6736(14)61933-4 · External reference
10.1002/hep4.1193
10.1002/hep4.1193 · External reference
10.1016/j.bmcl.2008.06.073
10.1016/j.bmcl.2008.06.073 · External reference
10.1021/acs.jmedchem.5b01161
10.1021/acs.jmedchem.5b01161 · External reference
10.1021/jm8014124
10.1021/jm8014124 · External reference
10.1002/hep.31205
10.1002/hep.31205 · External reference
Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH
2020 · External reference
Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH)
10.1021/acs.jmedchem.7b00907 · 2017 · External reference
10.1016/j.cct.2019.105889
10.1016/j.cct.2019.105889 · External reference
10.1021/acs.jmedchem.9b01621
10.1021/acs.jmedchem.9b01621 · External reference
10.1016/j.cmet.2013.01.003
10.1016/j.cmet.2013.01.003 · External reference
10.1039/c9md00264b
10.1039/c9md00264b · External reference
10.1016/j.jhep.2007.09.015
10.1016/j.jhep.2007.09.015 · External reference
10.1358/dot.2016.52.12.2571703
10.1358/dot.2016.52.12.2571703 · External reference
Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects
10.1016/s0168-8278(18)31427-2 · 2018 · External reference
10.1016/j.jhep.2017.01.013
10.1016/j.jhep.2017.01.013 · External reference
10.1053/j.gastro.2014.08.042
10.1053/j.gastro.2014.08.042 · External reference
Obeticholic acid: an update of its pharmacological activities in liver disorders
10.1007/164_2019_227 · 2019 · External reference
10.1016/s0092-8674(00)00062-3
10.1016/s0092-8674(00)00062-3 · External reference
10.1021/ci300459k
10.1021/ci300459k · External reference
Nonsteroidal FXR ligands: current status and clinical applications
10.1007/164_2019_232 · 2019 · External reference
10.1002/hep.30509
10.1002/hep.30509 · External reference
10.1002/cpdd.762
10.1002/cpdd.762 · External reference
A new FXR ligand chemotype with agonist/antagonist switch
10.1021/acsmedchemlett.0c00647 · 2021 · External reference
Target profile prediction: cross-activation of peroxisome proliferator-activated receptor (PPAR) and farnesoid X receptor (FXR)
10.1002/minf.200900009 · 2010 · External reference
Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists
10.2174/1568026614666141112103516 · 2014 · External reference
Structural investigation for optimization of anthranilic acid derivatives as partial FXR agonists by in silico approaches
10.3390/ijms17040536 · 2016 · External reference
10.1681/asn.2017020222
10.1681/asn.2017020222 · External reference
BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis
10.1038/srep42801 · 2017 · External reference
10.1124/mol.110.064501
10.1124/mol.110.064501 · External reference
10.3390/nu11051132
10.3390/nu11051132 · External reference
Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling
10.1371/journal.pone.0129866 · 2015 · External reference
10.1021/jm501273r
10.1021/jm501273r · External reference
10.1080/07391102.2018.1462735
10.1080/07391102.2018.1462735 · External reference
Farnesoid X receptor agonists as therapeutic target for cardiometabolic diseases
10.3389/fphar.2020.01247 · 2020 · External reference
Protein expression profiling identifies key proteins and pathways involved in growth inhibitory effects exerted by guggulsterone in human colorectal cancer cells
10.3390/cancers11101478 · 2019 · External reference
10.1177/0960327118817862
10.1177/0960327118817862 · External reference
10.1371/journal.pone.0030443
10.1371/journal.pone.0030443 · External reference
HS218 as an FXR antagonist suppresses gluconeogenesis by inhibiting FXR binding to PGC-1α promoter
10.1016/j.metabol.2018.03.016 · 2018 · External reference
Capsaicin improves glucose tolerance and insulin sensitivity through modulation of the gut microbiota-bile acid-FXR axis in type 2 diabetic db/db Mice
2019 · External reference
10.1021/acs.jmedchem.5b00342
10.1021/acs.jmedchem.5b00342 · External reference
10.1126/science.1072891
10.1126/science.1072891 · External reference
10.1021/jm3002718
10.1021/jm3002718 · External reference
Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates
10.1016/j.ejphar.2013.10.048 · 2014 · External reference
10.1016/j.bmc.2018.07.017
10.1016/j.bmc.2018.07.017 · External reference
10.1016/j.bmc.2014.04.014
10.1016/j.bmc.2014.04.014 · External reference
10.1021/acsmedchemlett.8b00534
10.1021/acsmedchemlett.8b00534 · External reference
10.1111/joim.12140
10.1111/joim.12140 · External reference
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
10.1038/ncomms10166 · 2015 · External reference
10.1074/jbc.m209323200
10.1074/jbc.m209323200 · External reference
10.1021/acsmedchemlett.0c00640
10.1021/acsmedchemlett.0c00640 · External reference
Andrographolide: chemical modification and its effect on biological activities
10.1016/j.bioorg.2019.103511 · 2020 · External reference
10.1021/np100489u
10.1021/np100489u · External reference
10.1053/j.gastro.2014.12.005
10.1053/j.gastro.2014.12.005 · External reference
10.1002/hep.29569
10.1002/hep.29569 · External reference
10.1007/s10620-016-4143-0
10.1007/s10620-016-4143-0 · External reference
10.1021/jm7015864
10.1021/jm7015864 · External reference
10.1073/pnas.0710981105
10.1073/pnas.0710981105 · External reference
10.1002/hep.24537
10.1002/hep.24537 · External reference
10.1038/s41586-020-2569-1
10.1038/s41586-020-2569-1 · External reference
